Exploring the Link between Varicella-Zoster Virus, Autoimmune Diseases, and the Role of Recombinant Zoster Vaccine
Biomolecules · 22.06.2024 · 14 (7) · 739
DOI: 10.3390/biom14070739 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biomolecules, online erschienen am 22.06.2024. Verfasst von Ryuhei Ishihara und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Immunology, Osaka Metropolitan University Graduate School of Medicine, Osaka 545-8585, Japan. Hauptthemen laut MEDLINE: Herpesvirus 3, Human, Autoimmune Diseases, Herpes Zoster Vaccine, Herpes Zoster. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 163 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The varicella-zoster virus (VZV) is a human neurotropic herpes virus responsible for varicella and herpes zoster (HZ). Following primary infection in childhood, VZV manifests as varicella (chickenpox) and enters a period of latency within the dorsal root ganglion. A compromised cellular immune response due to aging or immunosuppression triggers viral reactivation and the development of HZ (shingles). Patients with autoimmune diseases have a higher risk of developing HZ owing to the immunodeficiency associated with the disease itself and/or the use of immunosuppressive agents. The introduction of new immunosuppressive agents with unique mechanisms has expanded the treatment options for autoimmune diseases but has also increased the risk of HZ. Specifically, Janus kinase (JAK) inhibitors and anifrolumab have raised concerns regarding HZ. Despite treatment advances, a substantial number of patients suffer from complications such as postherpetic neuralgia for prolonged periods. The adjuvanted recombinant zoster vaccine (RZV) is considered safe and effective even in immunocompromised patients. The widespread adoption of RZV may reduce the health and socioeconomic burdens of HZ patients. This review covers the link between VZV and autoimmune diseases, assesses the risk of HZ associated with immunosuppressant use, and discusses the benefits and risks of using RZV in patients with autoimmune diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Immunology, Osaka Metropolitan University Graduate School of Medicine, Osaka 545-8585, Japan.
- Center for Senile Degenerative Disorders (CSDD), Osaka Metropolitan University Graduate School of Medicine, Osaka 545-8585, Japan.
ORCID-Profile: Ryu Watanabe, Mayu Shiomi, Tadashi Okano
Zitieren
APA
Ishihara, R., Watanabe, R., Shiomi, M., Katsushima, M., Fukumoto, K., Yamada, S., Okano, T., & Hashimoto, M. (2024). Exploring the Link between Varicella-Zoster Virus, Autoimmune Diseases, and the Role of Recombinant Zoster Vaccine. Biomolecules, 14(7), 739. https://doi.org/10.3390/biom14070739
Vancouver
Ishihara R, Watanabe R, Shiomi M, Katsushima M, Fukumoto K, Yamada S, et al. Exploring the Link between Varicella-Zoster Virus, Autoimmune Diseases, and the Role of Recombinant Zoster Vaccine. Biomolecules. 2024;14(7):739. doi:10.3390/biom14070739
BibTeX
@article{Ishihara2024,
author = {Ishihara, Ryuhei and Watanabe, Ryu and Shiomi, Mayu and Katsushima, Masao and Fukumoto, Kazuo and Yamada, Shinsuke and Okano, Tadashi and Hashimoto, Motomu},
title = {Exploring the Link between Varicella-Zoster Virus, Autoimmune Diseases, and the Role of Recombinant Zoster Vaccine},
journal = {Biomolecules},
year = {2024},
volume = {14},
number = {7},
pages = {739},
doi = {10.3390/biom14070739}
}
EUVIMED